NCT02998567 2025-08-17
HyPeR
Royal Marsden NHS Foundation Trust
Phase 1 Recruiting
Clinical Trials
3 trialsNCT03220477 2025-08-06
Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT03085849 2018-12-10
SGI-110 Plus Durvalumab/Tremelimumab in SCLC
Columbia University
Phase 1 Completed